A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of IBI362 in MASH subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 8-week screening period, a 60-week double-blind treatment period, and a 4-week follow-up period.

Timeline

Start

2025-07-01

Primary completion

2026-04-30

Completion

2027-07-22

Drugs

Indications